Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
NCT ID: NCT00625729
Last Updated: 2017-12-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
6 participants
INTERVENTIONAL
2008-01-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I/II trial is studying how well giving rituximab and chemotherapy followed by a donor natural killer cell infusion that has been treated in the laboratory with aldesleukin followed by aldesleukin works in treating patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To determine if allogeneic natural killer (NK) cells infused following chemoimmunotherapy can be safely expanded in vivo with aldesleukin.
Secondary
* To determine if interleukin-15 production at day 0 correlates with NK cells expansion.
* To determine overall response rate at 3 months.
* To determine time to progression and overall survival.
* To characterize the quantitative and qualitative toxicities of this treatment plan.
* To determine the incidence of donor products that do not meet release criteria and the NK cell numbers infused.
* To correlate clinical response with donor/recipient KIR ligand matching status, FcG receptor 3A genotype, and NK cells phenotype and function
* To determine pharmacodynamic and pharmacogenomic markers and correlate them with NK cell expansion and disease response.
OUTLINE:
* Conditioning regimen: Patients receive rituximab intravenously (IV) over 6-8 hours on days -8, -1, 6, and 13; fludarabine IV on days -6 to -2; and cyclophosphamide IV on day -5.
* Allogeneic natural killer (NK) cell administration: Patients receive aldesleukin-activated haploidentical NK cells IV over less than 1 hour on day 0. Within 4 hours after allogeneic NK cell infusion, patients receive aldesleukin subcutaneously (SC) 3 times a week for 6 doses. Patients also receive filgrastim (G-CSF) SC beginning on day 14 and continuing until absolute neutrophil count (ANC) is \> 2,500/mm³ for 2 consecutive days.
Patients who achieve a complete or partial response at 28 days are eligible for allogeneic stem cell transplantation. Patients who achieve initial response at 3 months, clinically benefit from treatment, but subsequently relapse are eligible for retreatment provided all eligibility criteria are met.
Blood samples are collected periodically for correlative laboratory studies. Patients with chronic lymphocytic leukemia (CLL) also undergo bone marrow aspiration periodically for correlative laboratory studies.
After completion of study treatment, patients are followed periodically for up to 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treated Patients
Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.
aldesleukin
Day 0-14, 10 million international units, 3 times per week for 6 doses
allogeneic natural killer cells
Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
rituximab
Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2
cyclophosphamide
60 mg/kg intravenous (IV) on Day -5.
fludarabine phosphate
Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
aldesleukin
Day 0-14, 10 million international units, 3 times per week for 6 doses
allogeneic natural killer cells
Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
rituximab
Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2
cyclophosphamide
60 mg/kg intravenous (IV) on Day -5.
fludarabine phosphate
Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Progression of NHL following at least 2 prior chemotherapy regimens, (must contain rituximab for all NHL and fludarabine for follicular NHL) defined as:
* failure to achieve partial remission (PR) with the last chemotherapy
* disease progression within 6 months following last chemotherapy
* Progression of CLL/SLL (small lymphocytic lymphoma) following at least 2 prior chemotherapy regimens (containing purine analogs ) in stage Rai III or IV or symptomatic disease.
* Relapsed NHL or CLL following stem cell transplantation for whom the option of donor lymphocyte infusion is not available or clinically indicated (e.g. recipients of autologous or umbilical cord blood \[UCB\] transplants).
* Available related HLA-haploidentical (human leukocyte antigen) natural killer (NK) cell adult donor by at least Class I serologic typing
* Karnofsky performance status \> 60%
* Measurable disease based on modified Response Evaluation Criteria In Solid Tumors (RECIST)
* Have acceptable organ function as defined within 28 days of enrollment:
* Hematologic: platelets ≥ 80,000 x 10\^9/L; hemoglobin ≥ 9g/dL, unsupported by transfusions; absolute neutrophil count (ANC) ≥ 1000 x 10\^9/L, unsupported by granulocyte-colony stimulating factor or granulocyte-macrophage colony-stimulating factor (G-CSF or GM-CS)F for 10 days or Neulasta for 21 days - the hematologic requirements are waived for patients with inadequate counts due to known bone marrow involvement by lymphoma who are otherwise eligible
* Renal: glomerular filtration rate (GFR) \> 50 ml/min
* Hepatic: alanine aminotransferase (ALT), aspartate aminotransferase (AST) \< 3 x upper limit of normal and total bilirubin \<3 mg/dl
* Pulmonary function: \>50% corrected carbon monoxide diffusing capacity (DLCO) and Forced Expiratory Volume in the first second (FEV1)
* Cardiac: no symptoms of uncontrolled cardiac disease, left ventricular ejection fraction \>40%
* Off prednisone or other immunosuppressive medications for at least 3 days prior to Day 0
* Women of childbearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment.
* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
Exclusion Criteria
* Active central nervous system (CNS) lymphoma/leukemia
* Active serious infection (pulmonary infiltrates or lesions are allowed only after the appropriate diagnostic testing is negative for infection or appropriate therapy was initiated for probable infection)
* Pleural effusion - large enough to be detectable on the chest x-ray
* Allergy to rituximab or IL-2
* Human immunodeficiency virus (HIV) and associated non-Hodgkins lymphoma (NHL)
* Active concurrent malignancy (except skin cancer) requiring systemic therapy in the past 2 years
* Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder
* Positive hepatitis B surface antigen (HBsAg). If Hepatitis B core antibody (HBcAb) is positive, Hepatitis B deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR) will be evaluated. Positive anti HBcAb and undetectable viral load does not exclude the patient.
* Any experimental therapy in the past 30 days
Donor Selection:
* Related donors (sibling, parent, offspring, parent or offspring of an HLA identical sibling) ≥ age 18 years
* Able and willing to undergo lymphapheresis
* HLA-haploidentical donor/recipient match. If time permits and multiple donors are available, preference will be given to the Killer-cell Immunoglobulin-like Receptors (KIR) ligand mismatched donor (as predicted by HLA typing).
* HIV-1, HIV-2 negative, Human T-lymphotropic virus Type I (HTLV-1), HTLV-2 negative, West Nile virus (WNV) negative, Hepatitis B and C negative
* Adequate organ function defined as:
* Hematologic: CBC/diff/platelet count near normal limits,
* Hepatic: ALT \< 2 x upper limit of normal,
* Not pregnant or lactating
* In general good health as determined by the study physician
* Able to give informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Masonic Cancer Center, University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Veronika Bachanova, MD
Role: PRINCIPAL_INVESTIGATOR
Masonic Cancer Center, University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT2007-12
Identifier Type: OTHER
Identifier Source: secondary_id
UMN-0707M13561
Identifier Type: OTHER
Identifier Source: secondary_id
2007LS064
Identifier Type: -
Identifier Source: org_study_id